pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Baseline characteristics of users of dabigatran vs. warfarin

Characteristics, % Before PS matched 1:1 PS matched


New dabigatran (n=721) Warfarin (n=2,401) p-value New dabigatran (n=721) Matched warfarin (n=721) p-value
Age, years 75.23±6.06 74.80±6.17 0.10 75.23±6.06 75.24±6.13 0.97
Age ≥ 75 years 52.57 48.31 0.05 52.57 53.26 0.83
Female 50.35 47.31 0.16 50.35 49.24 0.71
Comorbidity
Hypertension 78.92 74.05 0.01 78.92 79.06 1.00
Diabetes 17.06 15.12 0.22 17.06 13.73 0.09
Myocardial infarction 0.55 2.17 <0.01 0.55 0.69 1.00
Heart Failure 35.09 34.07 0.62 35.09 35.78 0.83
Ischemic stroke/Transient ischemic attack 0.42 0.04 0.04 0.42 0.14 0.63
Peripheral vascular disease 1.25 1.46 0.86 1.25 1.53 0.82
Dementia 0.28 0.54 0.54 0.28 0.14 1.00
Renal Disease 1.53 3.17 0.02 1.53 1.80 0.84
Chronic pulmonary disease 8.04 7.91 0.94 8.04 8.18 1.00
Liver disease 5.27 5.29 1.00 5.27 4.85 0.81
Cancer 0.69 1.00 0.66 0.69 0.97 0.77
depression 2.36 2.46 1.00 2.36 2.36 1.00
Hematological disorders (Coagulopathy, anemia) 3.61 5.83 0.02 3.61 3.33 0.89
Alcoholism 0.55 0.58 1.00 0.55 0.55 1.00
GI bleeding 0.69 0.33 0.19 0.69 0.55 1.00
Other bleeding 0.69 1.25 0.31 0.69 0.69 1.00
CHA2DS2-VASC score ≥ 2 98.06 94.63 <0.01 98.06 97.92 1.00
Medications,%
Digoxin 19.28 21.53 0.21 19.28 18.31 0.69
Clopidogrel 4.30 5.08 0.43 4.30 4.02 0.90
Antiplatelets 8.04 13.33 <0.01 8.04 7.35 0.69
ACEI/ARB 36.48 36.44 1.00 36.48 38.14 0.55
β-blockers 47.30 41.90 0.01 47.30 47.85 0.87
Ca channel blockers 9.43 9.95 0.72 9.43 11.10 0.34
Anti-arrhythmias 24.83 16.41 <0.01 24.83 24.55 0.95
Statins 32.45 28.65 0.05 32.45 31.76 0.82
Diabetes medication 10.68 9.12 0.22 10.68 7.77 0.07

PS, propensity score

Korean J Clin Pharm 2022;32:37-46 https://doi.org/10.24304/kjcp.2022.32.1.37
© 2022 Korean J Clin Pharm